Ethical Issues Related To The Access To Orphan Drugs In Brazil: The Case Of Mucopolysaccharidosis Type I

Background/Aims: Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was approved by the US Food and Drug Administration and the European Medicines Agency in 2003 and by the Brazilian National Health Surveillance Agency in 2005. Many Brazilian MPS I patients have been receiving laronidase despite the absence of a governmental policy regulating access to the drug. Epidemiological and treatment data concerning MPS I are scarce. This study aims to present a demographic profile of Brazilian patients with MPS I, describe the routes of access to laronidase in Brazil, and discuss associated ethical issues relating to public funding of orphan drugs. Methods: In this cross-sectional observational study, data were collected nationwide between January and September 2008 from physicians, public institutions and non-governmental organisations involved with diagnosis and treatment of MPS I, using two data collection instruments specifically designed for this purpose. Results: The minimum prevalence of MPS I in Brazil was estimated at 1/2 700 000. Most patients (69.8%) were younger than 15 years; 60 (88.2%) received laronidase. The most common route of access to the drug was through lawsuits (86.6%). Conclusions: In Brazil, MPS I is predominantly a paediatric illness. Even though the cost of laronidase treatment is not officially covered by the Brazilian government, most MPS I patients receive the drug, usually through litigation. This gives rise to major ethical conflicts concerning drug access in a low-resource context. The Brazilian health policy framework lacks evidence-based clinical protocols for the distribution of orphan drugs.374233239Neufeld, E., Muenzer, J., The mucopolysaccharidosis (2001) The metabolic and molecular basis of inherited disease, pp. 3421-3452. , Scriver CR, Beaudet AL, Sly S, et al, eds. 7th edn. New York, NY: McGraw-HillMeikle, P.J., Hopwood, J.J., Newborn screening for lysosomal storage: current issues and approaches (2005) Curr Med Literature, 5, pp. 41-48Dear, J.W., Lilitkarntakul, P., Webb, D.J., Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products (2006) Br J Pharmacol, 62, pp. 264-271Messina, C., Rampazzo, A., Cesaro, S., Eighteen-year follow-up of the first Italian MPS I patient treated with bone marrow transplantation (2008) Bone Marrow Transplant, 41, pp. 905-906Anon. Drugs for rare diseases: mixed assessment in Europe (2007) Prescrire Int, 16, pp. 36-42(2007), http://www.fda.gov/orphan/index.htm, US Food and Drug Administration (FDA). Developing products for rare diseases and conditions, (accessed 15 Dec)(2011) European Medicines Agency (EMA), , http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000050.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d12b, European Medicines Agency (EMA). Rare disease designation e Laronidase, (accessed 13 Jan)Wraith, J.E., Clarke, L.A., Beck, M., Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) (2004) J Pediatr, 144, pp. 581-588Schwartz, I., Martins, T.F., Federhen, A., A Rede MPS faz quatro anos: um panorama geral sobre a epidemiologia das MPS no Brasil (2008) Anais do XX Congresso Brasileiro de Genética Médica, p. 21. , Sociedade Brasileira de Genética Médica. Serrano Centro de Convenções, Gramado, RS, Brazil. 28 to 31 May 2008(2007), http://e-glossario.bvs.br/glossary/public/scripts/php/page_search.php?lang=&letter=M, Agência Nacional de Vigilância Sanitária (ANVISA). Glossário da Anvisa. Brazil, (accessed 15 Dec 2007)Goldim, J.R., O uso de drogas ainda experimentais em assistência: extensão de pesquisa, uso compassivo e acesso expandido (2008) Rev Panam Salud Publica, 23, pp. 198-206Horovitz, D.D., (2003) Atenção aos defeitos congênitos no Brasil: proposta para estruturação e integração da abordagem no sistema de saúde, , [dissertation]. Rio de Janeiro, Brazil: Instituto de Medicina Social, Universidade do Estado do Rio de JaneiroVieira, T., Schwartz, I., Muñoz, V., Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? (2008) Am J Med Genet A, 146 A, pp. 1741-1747Moore, D., Connock, M.J., Wraith, E., The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK (2008) Orphanet J Rare Dis, 3, p. 24(2007), http://www.ibge.gov.br/home/estatistica/populacao/contagem2007/contagem.pdf, Instituto Brasileiro de Geografia e Estatítica (IBGE). Contagem da população. Brazil, (accessed Jan 2009)Gericke, C.A., Riesberg, A., Busse, R., Ethical issues in funding orphan drug research and development (2005) J Med Ethics, 31, pp. 164-168Beutler, E., Lysosomal storage diseases: natural history and ethical and economic aspects (2006) Mol Genet Metab, 88, pp. 208-215Connock, M., Juarez-Garcia, A., Few, E., A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies of Fabry's disease and mucopolysaccharidosis type I (2006) Health Technol Assess, 10, pp. 3-4. , ix-113Pastores, G.M., Arn, P., Beck, M., The MPS I registry: design, methodology and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I (2007) Mol Genet Metab, 91, pp. 37-47(1988) Constituição da República Federativa do Brasil. Título VIII, capítulo II, seção II, "Da Saúde", , http://www.planalto.gov.br/ccivil_03/constituicao/constitui%C3%A7ao.htm, (accessed 12 Jan 2011)Tocqueville, A., (1985) A democracia na América, p. 240. , São Paulo: AbrilVieira, F.S., Zucchi, P., Distorções causadas pelas ações judiciais à política de medicamentos no Brasil (2007) Rev Saude Publica, 41, pp. 214-222Vieira, F.S., Ações judiciais e direito à saúde: reflexão sobre a observância aos princípios do SUS (2008) Rev Saude Publica, 42, pp. 365-369Resolução n8 16, de 13 de março de 2008 (2008) Diário Oficial da União, 1, p. 38. , Agência Nacional de Vigilância Sanitária (ANVISA), BrazilConnock, M., Burls, A., Frew, E., The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review (2006) Health Technol Assess, 10, pp. 3-4. , ix-136Picon, P., Prolla, P., Amaral, K., Doença de Gaucher (2002) Protocolos clínicos e diretrizes terapêuticas, pp. 217-234. , Picon P, Beltrame A, eds. Brasília: Ministério da SáudeWraith, J.E., Beck, M., Lane, R., Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 yearsresults of a multinational study of recombinant human alpha-L-iduronidase (laronidase) (2007) Pediatrics, 120, pp. e37-46Wraith, J.E., Hopwood, J.J., Fuller, M., Laronidase treatment of mucopolysaccharidosis I (2005) BioDrugs, 19, pp. 1-7Clarke, L.A., Wraith, J.E., Beck, M., Long term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I (2009) Pediatrics, 123, pp. 229-240Drummond, M.F., Wilson, D.A., Kanavos, P., Assessing the economic challenges posed by orphan drugs (2007) Int J Technol Assess Health Care, 23, pp. 36-42Raftery, J.P., Paying for costly pharmaceuticals: regulation of new drugs in Australia (2008) England and New Zealand. Med J Aust, 188, pp. 26-28Beauchamp, T.L., Childress, J.F., Beneficence (2001) Principles of biomedical ethics, pp. 165-224. , Beauchamp TL, Childress JF, eds. Oxford: Oxford University PressRawls, J., (1997) Uma teoria da justiça, , São Paulo: Martins FontesDaniels, N., (1996) Justice and justification: reflexive equilibrium in theory and practice, , New York: Cambridge University PressSen, A., (2000) Desenvolvimento como Liberdade, p. 10. , São Paulo: Companhia das LetrasSinger, P., (2002) Vida Ética, , Rio de Janeiro, Brazil: Ediour